GSK
Get informed when a big investor buys or sells
+ FollowJuly 28, 2026 - AI Summary
Undervalued by 88% based on the discounted cash flow analysis.
| Market cap | $101.55 Billion |
|---|---|
| Enterprise Value | $116.60 Billion |
| Dividend Yield | $1.82 (3.89%) |
| Earnings per Share | $2.82 |
| Beta | 0.29 |
| Outstanding Shares | 2,007,000,000 |
| P/E Ratio | 14.58 |
|---|---|
| PEG | -20.92 |
| Price to Sales | 0.32 |
| Price to Book Ratio | 5.98 |
| Enterprise Value to Revenue | 0.39 |
| Enterprise Value to EBIT | 6.29 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 1.03 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 119.03% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 17.22% |
|---|---|
| Total Invested | $75.90M▼ 99.58% |
| Investors Holding | 43▼ 1035.00% |
No data
GSK plc, a global healthcare and pharmaceutical leader with roots tracing back to 1715, is headquartered in Brentford, United Kingdom. Operating extensively across the UK, United States, and other international markets, its activities sp...